Today, Ichor is a vertically integrated contract research organization occupying multiple commercial facilities with complete pre-clinical R&D capabilities in LaFayette, NY and Potsdam, NY.
However, the company’s beginnings were far more modest.
Ichor is founded in an apartment living room
Ichor started with a functional living room laboratory complete with a specific-pathogen free vivarium in the apartment’s spare bedroom.
Ichor solved problems preventing development of the macular degeneration enzyme therapy program and acquired all rights.
Ichor acquires Finger Lakes Bio
Ichor acquired Finger Lakes Bio, a boutique protein engineering company.
Ichor launched Auctus. All the programs were fully funded with new investment rounds
Ichor acquires Woodland
Ichor acquired oncology and metabolic disease CRO, Woodland Biosciences.
Ichor rebrands as Ichor Life Sciences
Ichor Therapeutics rebranded as Ichor Life Sciences to emphasize service offerings.
Ichor leads founding investment in Lento Bio
Lento Bio launches with aim to develop anti-glycation drugs for presbyopia and diseases of aging.
We work towards a vision, not for a company
Building a successful company is a consequence of what we do in the pursuit of our vision. We are intrinsically motivated to create positive change in the world, and this philosophy extends to all aspects of company operations.
We build our own talent
Fundamental to the Ichor culture is an emphasis on professional development. Our team is not only evaluated on what they already know, but also on an ability to obtain new skills, work through diverse challenges, and anticipate and preempt complications within company workflows.
Team members are encouraged to embrace professional development opportunities, and to obtain cross training in areas unrelated to their core competencies.
Our Ichor Portfolio Companies
MitoChem is focused on developing treatments to address the effects of mitochondrial dysfunction in neurodegenerative diseases
Auctus Biologics, Inc. is developing an orally bioavailable antibody mimetic scaffold called a ribobody.
LentioBio is focused on developing small-molecule therapeutics to target crosslinks that cause tissues to stiffen with age.
Lysoclear, Inc. is developing a recombinant enzyme therapy that targets retinoid derivatives thought to contribute to various eye diseases.